Table 3 Adverse events during the adjuvant treatment phases. Values are expressed as numbers (percentage). Table presents grade I to IV adverse events in all patients during the adjuvant treatment phases. Adverse events are listed in descending order of frequency in the total patient population

Fatigue

90 (78.9%)

1 (0.8%)

91 (79.7%)

89 (77.45%)

0

89 (77.45%)

Loss of appetite

88 (77.2%)

0

88 (77.2%)

94 (81.7%)

0

94 (81.7%)

Nausea

77 (67.5%)

1 (0.8%)

78 (68.3%)

77 (67%)

0

77 (67%)

Leucopenia

49 (43.6%)

8 (7%)

57 (50.6%)

40 (34.8%)

15 (13%)

55 (47.8%)

Vomiting

43 (37.3%)

6 (4.4%)

49 (41.7%)

47 (40.9%)

1 (0.8%)

48 (41.7%)

Elevated TB

37 (32.5%)

1 (0.8%)

38 (33.3%)

40 (34.8%)

0

40 (34.8%)

Constipation

37 (32.5%)

1 (0.8%)

38 (33.3%)

39 (33.9%)

0

39 (33.9%)

Neutropenia

34 (29.8%)

11 (9.7%)

45 (39.5%)

37 (32.2%)

17 (14.8%)

54 (47%)

Anaemia

29 (25.4%)

0

29 (25.4%)

28 (24.3%)

1 (0.8%)

29 (25.1%)

Dry mouth

28 (24.6%)

0

28 (24.6%)

45 (39.1%)

0

45 (39.1%)

Pain

28 (24.7%)

0

28 (24.7%)

37 (32.2%)

0

37 (32.2%)

Alopecia

13 (11.4%)

0

13 (11.4%)

14 (12.2%)

0

14 (12.2%)

ALT/AST increased

12 (10.5%)

1 (0.8%)

13 (11.3%)

15 (11.3%)

0

15 (11.3%)

Elevated GGT

11 (9.6%)

2 (1.8%)

13 (11.4%)

9 (7.8%)

1 (0.8%)

10 (8.6%)

Diarrhoea

9 (7.9%)

0

9 (7.9%)

20 (17.4%)

0

20 (17.4%)

Thrombocytopaenia

6 (5.3%)

0

6 (5.3%)

15 (13%)

1 (0.8%)

16 (13.8%)

Elevated CRE

4 (3.5%)

0

4 (3.5%)

1 (0.9%)

0

1 (0.9%)

Weight-decrease

4 (3.5%)

0

4 (3.5%)

7 (6.1%)

0

7 (6.1%)

Rash

3 (2.6%)

0

3 (2.6%)

2 (1.7%)

0

2 (1.7%)

Arhythmia

2 (1.8%)

0

2 (1.8%)

2 (1.7%)

1 (0.8%)

3 (2.5%)

Pruritus

2 (1.8%)

0

2 (1.8%)

4 (3.5%)

0

4 (3.5%)

Elevated ALP

1 (0.8%)

0

1 (0.8%)

1 (0.9%)

0

1 (0.9%)